FIGURE 1.
FIGURE 2.
Immune-related adverse events
| Any grade | Grade 3 or higher | |
|---|---|---|
| Immune related adverse event | 11 (65) | 4 (24) |
| Thyroiditis | 5 (24) | 0 |
| Adrenal insufficiency | 2 (12) | 0 |
| Colitis | 4 (24) | 3 (18) |
| Rash | 3 (18) | 0 |
| Increase in AST and ALT level | 1 (6) | 0 |
| Pneumonitis | 1 (6) | 0 |
| Myocarditis | 1 (6) | 1 (6) |
Demographic and clinical characteristics of the patients at baseline
| Characteristic | N = 17 (100%) |
|---|---|
| Median age (range) - year | 59 (32-73) |
| Gender | |
| Male | 14 (82) |
| Female | 3 (18) |
| ECOG performance status | |
| 0 | 15 (88) |
| 1 | 2 (12) |
| Disease stage at initial diagnosis | |
| II | 4 (24) |
| III | 13 (76) |
| Disease stage at initial diagnosis | |
| Oesophagus | 9 (53) |
| Gastroesophageal junction | 8 (47) |
| Histological type | |
| Adenocarcinoma | 12 (71) |
| Squamous-cell carcinoma | 5 (29) |
| Pathological lymph-node status | |
| ypN0 | 6 (35) |
| ≥ ypN1 | 11 (65) |
| Pathological tumour status | |
| ypT0 | 1 (6) |
| ypT1 or ypT2 | 5 (29) |
| ypT3 or ypT4 | 11 (65) |
| Tumour-cell PD-L1 expression | |
| < 1 | 5 (29) |
| ≥ 1 | 12 (71) |